Literature DB >> 12574945

Phenotypical variability of expanded alleles in the TATA-binding protein gene. Reduced penetrance in SCA17?

Christine Zühlke1, Ulrike Gehlken, Yorck Hellenbroich, Eberhard Schwinger, Katrin Bürk.   

Abstract

Trinucleotide expansions in the gene for the TATA-binding protein (TBP) have recently been described in cerebellar ataxia associated with dementia, pyramidal tract and basal ganglia symptoms. Expansions above 45 repeat units are commonly considered pathological, causing SCA17. Here, we present a German kindred with four siblings affected by cerebellar ataxia, chorea and dementia. Molecular genetic analysis yielded an expanded SCA17 allele coding for 48 glutamine residues that was transmitted from the mother to all of her six children. Apparently, the expanded allele does not cosegregate with the disease phenotype since the mother and two of the siblings do not show any clinical abnormality. This appears to be the first description of non-penetrance in SCA17.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12574945     DOI: 10.1007/s00415-003-0958-7

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  9 in total

1.  Spinocerebellar ataxia type 17 in a patient from an Indian kindred.

Authors:  Dietrich Haubenberger; Daniela Prayer; Peter Bauer; Walter Pirker; Alexander Zimprich; Eduard Auff
Journal:  J Neurol       Date:  2006-09-13       Impact factor: 4.849

2.  Downregulation of proteins involved in the endoplasmic reticulum stress response and Nrf2-ARE signaling in lymphoblastoid cells of spinocerebellar ataxia type 17.

Authors:  Li-Ching Lee; Yu-Ting Weng; Yih-Ru Wu; Bing-Wen Soong; Yung-Che Tseng; Chiung-Mei Chen; Guey-Jen Lee-Chen
Journal:  J Neural Transm (Vienna)       Date:  2014-01-11       Impact factor: 3.575

Review 3.  The wide spectrum of spinocerebellar ataxias (SCAs).

Authors:  Mario-Ubaldo Manto
Journal:  Cerebellum       Date:  2005       Impact factor: 3.847

Review 4.  Spinocerebellar ataxia type 17 is caused by mutations in the TATA-box binding protein.

Authors:  Christine Zühlke; Katrin Bürk
Journal:  Cerebellum       Date:  2007-01-19       Impact factor: 3.847

5.  Spinocerebellar ataxia 17 (SCA17) and Huntington's disease-like 4 (HDL4).

Authors:  Giovanni Stevanin; Alexis Brice
Journal:  Cerebellum       Date:  2008       Impact factor: 3.847

6.  Spinocerebellar ataxia type 17 (SCA17): oculomotor phenotype and clinical characterization of 15 Italian patients.

Authors:  Caterina Mariotti; Dario Alpini; Roberto Fancellu; Paola Soliveri; Marina Grisoli; Sabrina Ravaglia; Carlo Lovati; Vincenza Fetoni; Giorgio Giaccone; Alessia Castucci; Franco Taroni; Cinzia Gellera; Stefano Di Donato
Journal:  J Neurol       Date:  2007-10-15       Impact factor: 4.849

7.  Spinocerebellar ataxia type 17: report of a family with reduced penetrance of an unstable Gln49 TBP allele, haplotype analysis supporting a founder effect for unstable alleles and comparative analysis of SCA17 genotypes.

Authors:  Christine Zühlke; Andreas Dalski; Eberhard Schwinger; Ulrich Finckh
Journal:  BMC Med Genet       Date:  2005-07-01       Impact factor: 2.103

8.  Analysis of SCA8, SCA10, SCA12, SCA17 and SCA19 in patients with unknown spinocerebellar ataxia: a Thai multicentre study.

Authors:  Lulin Choubtum; Pirada Witoonpanich; Suchat Hanchaiphiboolkul; Roongroj Bhidayasiri; Onanong Jitkritsadakul; Sunsanee Pongpakdee; Suppachok Wetchaphanphesat; Pairoj Boonkongchuen; Teeratorn Pulkes
Journal:  BMC Neurol       Date:  2015-09-15       Impact factor: 2.474

9.  Complexity of the Genetics and Clinical Presentation of Spinocerebellar Ataxia 17.

Authors:  Suran Nethisinghe; Wei N Lim; Heather Ging; Anna Zeitlberger; Rosella Abeti; Sally Pemble; Mary G Sweeney; Robyn Labrum; Charisse Cervera; Henry Houlden; Elisabeth Rosser; Patricia Limousin; Angus Kennedy; Michael P Lunn; Kailash P Bhatia; Nicholas W Wood; John Hardy; James M Polke; Liana Veneziano; Alfredo Brusco; Mary B Davis; Paola Giunti
Journal:  Front Cell Neurosci       Date:  2018-11-23       Impact factor: 5.505

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.